Compile Data Set for Download or QSAR
maximum 50k data
Found 308 Enz. Inhib. hit(s) with all data for entry = 3496
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185324(US10011588, Example 145 | US10689373, Example 145 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185334(US10011588, Example 156 | US10689373, Example 156 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185313(US10011588, Example 132 | US10689373, Example 132 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185261(US10011588, Example 77 | US10689373, Example 77 | ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US10011588, Example 142 | US10689373, Example 142 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185323(US10011588, Example 144 | US10689373, Example 144 ...)
Affinity DataIC50:  13nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185306(US10011588, Example 125 | US10689373, Example 125 ...)
Affinity DataIC50:  14nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185304(US10011588, Example 123 | US10689373, Example 123 ...)
Affinity DataIC50:  18nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185269(US10011588, Example 85 | US10689373, Example 85 | ...)
Affinity DataIC50:  18nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185327(US10011588, Example 148 | US10689373, Example 148 ...)
Affinity DataIC50:  19nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185262(US10011588, Example 78 | US10689373, Example 78 | ...)
Affinity DataIC50:  19nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185279(US10011588, Example 95 | US10689373, Example 95 | ...)
Affinity DataIC50:  19nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185266(US10011588, Example 82 | US10689373, Example 82 | ...)
Affinity DataIC50:  21nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185292(US10011588, Example 109 | US10689373, Example 109 ...)
Affinity DataIC50:  21nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185305(US10011588, Example 124 | US10689373, Example 124 ...)
Affinity DataIC50:  21nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185268(US10011588, Example 84 | US10689373, Example 84 | ...)
Affinity DataIC50:  22nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185301(US10011588, Example 119 | US10689373, Example 119 ...)
Affinity DataIC50:  22nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185326(US10011588, Example 147 | US10689373, Example 147 ...)
Affinity DataIC50:  24nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185291(US10011588, Example 108 | US10689373, Example 108 ...)
Affinity DataIC50:  24nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185337(US10011588, Example 159 | US10689373, Example 159 ...)
Affinity DataIC50:  25nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185328(US10011588, Example 149 | US10689373, Example 149 ...)
Affinity DataIC50:  25nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185290(US10011588, Example 107 | US10689373, Example 107 ...)
Affinity DataIC50:  27nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185277(US10011588, Example 94 | US10689373, Example 94 | ...)
Affinity DataIC50:  28nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185338(US10011588, Example 160 | US10689373, Example 160 ...)
Affinity DataIC50:  29nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185330(US10011588, Example 151 | US10689373, Example 151 ...)
Affinity DataIC50:  29nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185289(US10011588, Example 106 | US10689373, Example 106 ...)
Affinity DataIC50:  29nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185317(US10011588, Example 138 | US10689373, Example 138 ...)
Affinity DataIC50:  30nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185318(US10011588, Example 139 | US10689373, Example 139 ...)
Affinity DataIC50:  32nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185216(US10011588, Example 32 | US10689373, Example 32 | ...)
Affinity DataIC50:  32nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185303(US10011588, Example 122 | US10689373, Example 122 ...)
Affinity DataIC50:  32nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185260(US10011588, Example 76 | US10689373, Example 76 | ...)
Affinity DataIC50:  33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US10011588, Example 129 | US10689373, Example 129 ...)
Affinity DataIC50:  33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185294(US10011588, Example 111 | US10689373, Example 111 ...)
Affinity DataIC50:  34nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185316(US10011588, Example 137 | US10689373, Example 137 ...)
Affinity DataIC50:  34nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185263(US10011588, Example 79 | US10689373, Example 79 | ...)
Affinity DataIC50:  35nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185224(US10011588, Example 40 | US10689373, Example 40 | ...)
Affinity DataIC50:  35nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185319(US10011588, Example 140 | US10689373, Example 140 ...)
Affinity DataIC50:  35nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185264(US10011588, Example 80 | US10689373, Example 80 | ...)
Affinity DataIC50:  35nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185277(US10011588, Example 94 | US10689373, Example 94 | ...)
Affinity DataIC50:  35nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185241(US10011588, Example 57 | US10689373, Example 57 | ...)
Affinity DataIC50:  38nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185312(US10011588, Example 131 | US10689373, Example 131 ...)
Affinity DataIC50:  39nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM402146(US10011588, Example 105 | [(1S,2S)-2-{[3-Fluoro-5-...)
Affinity DataIC50:  39nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 308 total ) | Next | Last >>
Jump to: